Next Article in Journal
Role of Matrix Metalloproteinases 7 in the Pathogenesis of Laryngopharyngeal Reflux: Decreased E-cadherin in Acid exposed Primary Human Pharyngeal Epithelial Cells
Next Article in Special Issue
Osteoporosis in Rheumatic Diseases
Previous Article in Journal
The CCR4–NOT Deadenylase Complex Maintains Adipocyte Identity
Previous Article in Special Issue
MicroRNA-29a Counteracts Glucocorticoid Induction of Bone Loss through Repressing TNFSF13b Modulation of Osteoclastogenesis
Open AccessReview

Anticoagulants and Osteoporosis

Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2019, 20(21), 5275;
Received: 24 September 2019 / Revised: 20 October 2019 / Accepted: 21 October 2019 / Published: 24 October 2019
(This article belongs to the Special Issue Secondary Osteoporosis in Adults)
Anticoagulant agents are widely used in the treatment of thromboembolic events and in stroke prevention. Data about their effects on bone tissue are in some cases limited or inconsistent (oral anti-vitamin K agents), and in others are sufficiently strong (heparins) to suggest caution in their use in subjects at risk of osteoporosis. This review analyses the effects of this group of drugs on bone metabolism, on bone mineral density, and on fragility fractures. A literature search strategy was developed by an experienced team of specialists by consulting the MEDLINE platform, including published papers and reviews updated to March 2019. Literature supports a detrimental effect of heparin on bone, with an increase in fracture rate. Low molecular weight heparins (LMWHs) seem to be safer than heparin. Although anti-vitamin K agents (VKAs) have a significant impact on bone metabolism, and in particular, on osteocalcin, data on bone mineral density (BMD) and fractures are contrasting. To date, the new direct oral anticoagulants (DOACs) are found to safe for bone health. View Full-Text
Keywords: osteoporosis; fracture; anticoagulant agents; heparin; low molecular weight heparins (LMWHs); warfarin osteoporosis; fracture; anticoagulant agents; heparin; low molecular weight heparins (LMWHs); warfarin
Show Figures

Figure 1

MDPI and ACS Style

Signorelli, S.S.; Scuto, S.; Marino, E.; Giusti, M.; Xourafa, A.; Gaudio, A. Anticoagulants and Osteoporosis. Int. J. Mol. Sci. 2019, 20, 5275.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop